The Latest Updates from CNSide Diagnostics
CNSide at the NCCN Breast Cancer Conference
CNSide Diagnostics recently attended the NCCN 2026 Breast Cancer Conference hosted by the National Comprehensive Cancer Network to connect with clinicians, researchers, and oncology professionals focused on advancing breast cancer care. During the event, the CNSide...
CNSide Supports World Cancer Day: Advancing Awareness and Equity in Cancer Care
Each year on World Cancer Day, the global oncology community comes together to raise awareness, support patients, and advocate for more equitable access to cancer care. CNSide Diagnostics is proud to stand alongside clinicians, researchers, patient advocates, and...
CNSide Diagnostics to Participate in the Inaugural Brain & Spine Metastases Conference
CNSide Diagnostics is looking forward to participating in the Inaugural Brain & Spine Metastases Conference this week in Miami. The event will bring together leading clinicians, researchers, and oncology specialists focused on improving the understanding and...
Leptomeningeal Metastases: New Educational Resource for Patients and Physicians
CNSide Diagnostics and Plus Therapeutics are proud to collaborate with the Leptomeningeal Cancer Foundation to introduce a new educational resource designed to help patients, caregivers, and healthcare professionals better understand leptomeningeal metastases (LM)....
Plus Therapeutics Expands CNSide® TCE Test Availability to 48 States
New lab licenses strengthen nationwide access to CNS oncology diagnostics Plus Therapeutics (NASDAQ: PSTV) has announced a major regulatory and commercialization milestone with the expansion of laboratory licenses for its CNSide® Cerebrospinal Fluid (CSF) Tumor Cell...
Two New Strategic Executive Hires
Expanding operational and regulatory expertise to support commercialization and growth Plus Therapeutics (NASDAQ: PSTV) today announced two key leadership additions to CNSide Diagnostics, its wholly-owned subsidiary, further strengthening the company’s operational...
Houston Business Journal
Strengthening CNS oncology diagnostics at the heart of America’s largest medical ecosystem CNSide Diagnostics, a subsidiary of Plus Therapeutics (NASDAQ: PSTV), has officially expanded into Levit Green, a premier life sciences innovation campus developed by Hines in...
Progress, Potential, and Possibilities Interview
In the evolving landscape of central nervous system (CNS) oncology, the integration of advanced diagnostic technologies with precision therapeutic innovation is reshaping how clinicians detect, monitor, and manage complex CNS cancers. At CNSide Diagnostics, we are...
KOL Interview with Healio
Accurately detecting and quantifying tumor cells in cerebrospinal fluid (CSF) is essential for diagnosing, monitoring, and managing central nervous system (CNS) malignancies—particularly leptomeningeal metastases (LM) and other aggressive cancers that spread to the...
CNSide® CSF Assay Now Covered by Humana, Expanding National Access to Precision CNS Cancer Diagnostics
CNSide Diagnostics is pleased to announce a major milestone in expanding patient access to advanced CNS cancer diagnostics. Humana (NYSE: HUM)—one of the nation’s largest health insurers—has entered into a national agreement with Plus Therapeutics, providing coverage...